Alzheimer’s disease (AD) is a neurodegenerative disorder categorized by the progressive loss of cognitive function, with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) as key therapeutic targets. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.